Pfizer led the pack with fines for five drugs, while the other companies had one to two products.
One of the provisions of the Inflation Reduction Act, which was passed in August and hit pharma lobby groups hard, allows the federal government to hand drugmakers tax penalties if prices for their prescription drugs in Medicare Part D outpace the rate of inflation.
The drugs outlined by the White House may have lower coinsurances for Part D beneficiaries from April 1 to June 30, HHS said, with savings between $2 and $390 per dose.
Here are the 27 products and their drugmakers:
1. Abelcet (Leadiant Biosciences)
2. Akynzeo (Helsinn Therapeutics)
3. Atgam (Pfizer)
4. Aveed (Endo Pharmaceuticals)
5. Bicillin C-R (Pfizer)
6. Bicillin L-A (Pfizer)
7. Carnitor (Leadiant Biosciences)
8. Cytogam (Saol Therapeutics)
9. Elzonris (Stemline Therapeutics)
10. Fetroja (Shionogi & Co.)
11. Flebogamma DIF (Grifols)
12. Folotyn (Allos Therapeutics)
13. Fragmin (Pfizer)
14. Humira (AbbVie)
15. Leukine (Partner Therapeutics)
16. Minocin (Hovione)
17. Mircera (Roche)
18. Nipent (Pfizer)
19. Padcev (Agensys and Seagen)
20. Rybrevant (Johnson & Johnson)
21. Signifor LAR (Recordati)
22. Sylvant (EUSA Pharma)
23. Tecartus (Kite Pharma)
24. Winrho SDF (Cangene)
25. Xiaflex (Endo International)
26. Xipere (Clearside Biomedical)
27. Yescarta (Kite Pharma)
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
